Nuveen LLC Makes New $302,000 Investment in Caribou Biosciences, Inc. $CRBU

Nuveen LLC acquired a new position in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) during the 1st quarter, according to its most recent 13F filing with the SEC. The fund acquired 330,831 shares of the company’s stock, valued at approximately $302,000. Nuveen LLC owned about 0.36% of Caribou Biosciences as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Two Sigma Investments LP increased its holdings in Caribou Biosciences by 23.7% during the 4th quarter. Two Sigma Investments LP now owns 1,118,696 shares of the company’s stock worth $1,779,000 after purchasing an additional 214,239 shares during the last quarter. Ameriprise Financial Inc. purchased a new stake in Caribou Biosciences during the 4th quarter worth approximately $649,000. Nuveen Asset Management LLC increased its holdings in Caribou Biosciences by 23.6% during the 4th quarter. Nuveen Asset Management LLC now owns 330,831 shares of the company’s stock worth $526,000 after purchasing an additional 63,096 shares during the last quarter. Barclays PLC increased its holdings in Caribou Biosciences by 12.0% during the 4th quarter. Barclays PLC now owns 145,417 shares of the company’s stock worth $231,000 after purchasing an additional 15,578 shares during the last quarter. Finally, Northern Trust Corp increased its position in shares of Caribou Biosciences by 3.4% in the 4th quarter. Northern Trust Corp now owns 714,737 shares of the company’s stock worth $1,136,000 after purchasing an additional 23,531 shares during the last quarter. 77.51% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised shares of Caribou Biosciences from a “sell” rating to a “hold” rating in a research report on Sunday, August 24th. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Caribou Biosciences presently has an average rating of “Buy” and a consensus price target of $6.67.

Caribou Biosciences Stock Up 1.1%

Shares of NASDAQ:CRBU opened at $1.87 on Friday. Caribou Biosciences, Inc. has a fifty-two week low of $0.66 and a fifty-two week high of $3.00. The firm has a 50-day simple moving average of $1.85 and a 200 day simple moving average of $1.30. The company has a market cap of $174.13 million, a PE ratio of -1.05 and a beta of 2.54.

Caribou Biosciences (NASDAQ:CRBU) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.05. Caribou Biosciences had a negative return on equity of 62.35% and a negative net margin of 1,800.93%.The business had revenue of $2.67 million during the quarter, compared to analyst estimates of $1.64 million. As a group, research analysts forecast that Caribou Biosciences, Inc. will post -1.64 EPS for the current fiscal year.

Caribou Biosciences Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.